What Biostasis Technologies does

Biostasis Technologies is a New York City-based, non-profit human cryopreservation R&D organization founded in 2022 with five employees. Its chartered objectives cover experimental and theoretical research into hypothermic tissue stabilization of legally deceased or terminally ill patients for organ preservation, brain banking, anatomical donation, and human biostasis; publication of research reports, protocols, and clinical standards; education, training, and certification of medical professionals in stabilization delivery; and assistance with the formation of regional stabilization delivery organizations along with protocol compliance monitoring.

The organization's core technology centers on ice-free preservation methods for the brain, including cryoprotective perfusion and vitrification, and on distinguishing Type I (ideal, prompt) and Type II (delayed, suboptimal) cryonics procedures. It delivers four named offerings: CryoRegistry, a secure centralized database tracking individuals related to cryonics; the S-MIX Calculator, which quantifies a patient's ischemic exposure as equivalent normothermic ischemia duration; the educational reference "Philosophy and Biology of Human Cryopreservation" by Brian Wowk, Ph.D.; and a community newsletter. Distribution is indirect: Biostasis does not perform patient procedures itself but trains and certifies the medical professionals who do.

The business model is non-commercial in orientation: pricing is not publicly disclosed, no paying customers or revenue figures are identified, and the entity operates as an R&D and standards-setting body. GTM is limited to top-of-funnel newsletter and educational content, mid-funnel calculator tools, and bottom-of-funnel registry participation. Leadership is led by CEO Aschwin de Wolf (also CEO of Advanced Neural Biosciences), with Max More, Ph.D. (former President and CEO of Alcor Life Extension Foundation, 2011-2020) as Director of Communications, and medical advisory from Dr. Wm Ted Brown (MD, PhD; Johns Hopkins, Harvard Medical School), who also advises Southern Cryonics and Tomorrow Bio.

Name

Biostasis Technologies

Legal name

Biostasis Technologies

Website

https://biostasistechnologies.org

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Biostasis Technologies is a non-profit R&D organization that develops hypothermic tissue stabilization and cryopreservation protocols, trains and certifies medical professionals, and operates CryoRegistry and the S-MIX Calculator for the cryonics community.

Ownership category

akta.pro rank

Product category

Cryopreservation Research & Standards

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Blood and Organ Banks (621991)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN)

akta.pro secondary industry

Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ)

Keywords

• Human cryopreservation research
• Cryonics protocol development
• Medical certification training
• Tissue stabilization procedures
• Cryopreservation standards body

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels4 records

Core offering

Biostasis Technologies is a non-profit human cryopreservation R&D organization that conducts experimental and theoretical research on hypothermic tissue stabilization, publishes protocols and clinical standards, trains and certifies medical professionals to perform stabilization delivery services, and assists in forming and monitoring regional cryonics delivery organizations. Its named assets include the CryoRegistry (secure registrant database), the S-MIX Calculator (ischemic exposure measurement tool), a newsletter, and educational philosophy content.

Product overview

Biostasis Technologies is a human cryopreservation R&D organization offering a suite of services including the CryoRegistry (a secure registry for cryonics-related individuals), the S-MIX Calculator (a tool for measuring patient ischemic exposure), educational content on cryopreservation philosophy and biology, and a newsletter for community communication. The company focuses on experimental research to improve hypothermic tissue stabilization for organ preservation, brain banking, anatomical donation, and human biostasis, along with publishing protocols and clinical standards.

Differentiator

Problem solved

Functional benefit

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Oregon Cryonics: US-based nonprofit building regional cryopreservation capacity in the Pacific Northwest, with similar mission and a comparable need for shared protocols, training, and certification.
• Cryonics Institute: Michigan-based nonprofit cryonics organization offering whole-body cryopreservation services. Closely comparable mission and customer base to Biostasis' stakeholders, and would be a natural user of Biostasis' protocols and certification frameworks.
• Alcor Life Extension Foundation: Alcor is the largest US-based full-service cryonics organization offering whole-body and neuropreservation. Biostasis' Director of Communications Max More was Alcor's President and CEO from 2011-2020, and Biostasis develops protocols and certifications that Alcor's operations could adopt.
• KrioRus: Russian cryonics organization providing whole-body and neuro cryopreservation services. Operates in a different regulatory regime but offers the same core service and would be a relevant peer for protocol benchmarking.
• Southern Cryonics: Australia's first cryonics organization, in build-out phase, offering standby and cryopreservation services. Dr. Wm Ted Brown is a founding member, making this a direct peer in mission and a likely adopter of Biostasis' protocols.
• Tomorrow Bio: European cryonics provider offering standby, stabilization, and long-term storage with a field-team model. Shares Dr. Wm Ted Brown (Biostasis Medical Advisor) as an advisor and would benefit directly from Biostasis' protocol development.
• Suspended Animation: Florida-based company providing cryonics standby and stabilization services to multiple cryonics organizations. Directly comparable in the stabilization phase of the cryonics workflow that Biostasis' R&D and training programs target.

Emerging players

• X-Therma: Cryopreservation technology company developing novel cryoprotectants and storage solutions for cells, tissues, and organs. Adjacent in technology domain and a potential partner or competitor for Biostasis' protocol IP.
• Advanced Neural Biosciences: Biostasis CEO Aschwin de Wolf also runs Advanced Neural Biosciences, which conducts related cryobiology and neural tissue research. Highly overlapping in personnel and mission though narrower in scope.

Broad incumbents

• 21st Century Medicine: Cryobiology R&D company with a long track record in organ and tissue vitrification research that underpins modern cryopreservation. Broader in scientific scope than Biostasis but directly relevant as a research reference point for vitrification protocols.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/biostasis-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biostasis Technologies